Mixed sentiment is observed on **Intuitive Surgical (ISRG)** after varying stock performance. Despite recent share price weakness, some analysts express confidence in its valuation, particularly post strong Q4 and da Vinci 5 cardiac clearance. While its 2026 guidance appears lackluster, some believe buying on the dip will be profitable. Optimism from Wall Street analysts fuels the question of whether ISRG is a buy. Their **top-line growth** potential for 2026 and its status as a bullish bet are factors to consider, especially with its **record revenue** in Q4 2025. Several brokers suggest investing, backed by new FDA clearances. However, its cautious management commentary, investor concerns, and slips in share price have caused some decline. ISRG has demonstrated strong Q4 procedure growth, remarkable earnings surprises, and da Vinci 5 demand. However, opinions remain divided on whether or not it is a good buy amid its Wall Street performance. While insider buying suggests growth potential, recent guidance miss has led to falling share prices. **Robust Revenue growth** and bullish sentiment from Morgan Stanley offers a glimmer of hope.
Intuitive Surgical ISRG News Analytics from Fri, 03 Oct 2025 07:00:00 GMT to Sat, 07 Feb 2026 06:00:40 GMT -
Rating 4
- Innovation 7
- Information 8
- Rumor -2
